Stocks
Editas Medicine Financial Statements (EDIT) |
||||||||||
| Editas Medicinesmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 05.05.2023 | 02.08.2023 | 03.11.2023 | 28.02.2024 | 08.05.2024 | 08.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 9.85 | 2.89 | 5.34 | 60.0 | 1.14 | 69.4 | |||
| Operating Income, bln rub | -51.0 | -44.1 | -45.0 | -24.0 | -67.0 | -180.1 | ||||
| EBITDA, bln rub | ? | -51.0 | -44.1 | -45.0 | -22.5 | -65.6 | -177.2 | |||
| Net profit, bln rub | ? | -45.6 | -40.3 | -45.0 | -18.9 | -62.0 | -166.1 | |||
| OCF, bln rub | ? | -35.8 | -38.7 | -35.5 | -22.2 | -49.9 | -146.3 | |||
| CAPEX, bln rub | ? | 1.84 | 1.33 | 0.239 | 1.31 | 1.87 | 4.75 | |||
| FCF, bln rub | ? | -37.6 | -40.0 | -35.7 | -23.5 | -51.7 | -151.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 60.8 | 47.0 | 55.5 | 82.5 | 66.7 | 251.7 | ||||
| Cost of production, bln rub | 1.54 | 1.54 | 1.51 | 1.47 | 1.41 | 5.93 | ||||
| R&D, bln rub | 37.8 | 29.8 | 5.34 | 68.1 | 47.4 | 150.6 | ||||
| Interest expenses, bln rub | 3.47 | 0.000 | 0.000 | 3.47 | 0.000 | 3.47 | ||||
| Assets, bln rub | 464.1 | 542.0 | 504.7 | 499.2 | 440.3 | 440.3 | ||||
| Net Assets, bln rub | ? | 317.5 | 399.9 | 360.5 | 349.1 | 294.4 | 294.4 | |||
| Debt, bln rub | 37.1 | 37.2 | 34.6 | 36.5 | 34.1 | 34.1 | ||||
| Cash, bln rub | 401.8 | 480.0 | 446.4 | 323.1 | 296.2 | 296.2 | ||||
| Net debt, bln rub | -364.6 | -442.8 | -411.8 | -286.6 | -262.0 | -262.0 | ||||
| Ordinary share price, rub | 7.25 | 8.23 | 7.80 | 10.1 | 7.42 | 7.04 | ||||
| Number of ordinary shares, mln | 68.9 | 71.4 | 81.6 | 81.7 | 81.9 | 81.9 | ||||
| Market cap, bln rub | 500 | 587 | 637 | 828 | 608 | 577 | ||||
| EV, bln rub | ? | 135 | 145 | 225 | 541 | 346 | 315 | |||
| Book value, bln rub | 317 | 400 | 360 | 349 | 294 | 294 | ||||
| EPS, rub | ? | -0.66 | -0.56 | -0.55 | -0.23 | -0.76 | -2.03 | |||
| FCF/share, rub | -0.55 | -0.56 | -0.44 | -0.29 | -0.63 | -1.84 | ||||
| BV/share, rub | 4.61 | 5.60 | 4.41 | 4.27 | 3.59 | 3.59 | ||||
| EBITDA margin, % | ? | -517.3% | -1 527% | -843.7% | -37.5% | -5 778% | -255.3% | |||
| Net margin, % | ? | -462.6% | -1 396% | -843.7% | -31.4% | -5 458% | -239.4% | |||
| FCF yield, % | ? | -33.5% | -28.8% | -24.5% | -16.5% | -24.8% | -26.2% | |||
| ROE, % | ? | -65.3% | -48.7% | -51.6% | -42.9% | -56.4% | -56.4% | |||
| ROA, % | ? | -44.6% | -35.9% | -36.8% | -30.0% | -37.7% | -37.7% | |||
| P/E | ? | -2.41 | -3.02 | -3.43 | -5.53 | -3.66 | -3.47 | |||
| P/FCF | -2.98 | -3.47 | -4.08 | -6.05 | -4.03 | -3.82 | ||||
| P/S | ? | 21.9 | 30.4 | 25.9 | 10.6 | 8.76 | 8.31 | |||
| P/BV | ? | 1.57 | 1.47 | 1.77 | 2.37 | 2.07 | 1.96 | |||
| EV/EBITDA | ? | -0.61 | -0.67 | -1.11 | -3.33 | -1.95 | -1.78 | |||
| Debt/EBITDA | 1.64 | 2.07 | 2.02 | 1.76 | 1.48 | 1.48 | ||||
| R&D/CAPEX, % | 2 055% | 2 234% | 2 233% | 5 210% | 2 532% | 3 170% | ||||
| CAPEX/Revenue, % | 18.7% | 46.2% | 4.48% | 2.18% | 164.8% | 6.84% | ||||
| Editas Medicine shareholders | ||||||||||
